试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-20
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4
编号:NCT03381859登记状态:入组前撤回企业 / 申办者:University of Maryland, Baltimore
药物 / 成分:Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
登记的停止原因(原文):HCV treatment expansion occurred in Egypt
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-17
Platelet-rich Plasma Injections for Persistent Medial Knee Pain After Total Knee Arthroplasty
编号:NCT03225092登记状态:入组前撤回企业 / 申办者:Ohio State University
药物 / 成分:Ultrasound-guided platelet rich plasma injection
登记的停止原因(原文):Unable to recruit enough study participants
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-16
Periodontal Profile of Hypogonadic Men
编号:NCT03176537登记状态:入组前撤回企业 / 申办者:Universidade Federal do Paraná
药物 / 成分:Testosterone gel、Placebos
登记的停止原因(原文):No eligible participants for the RCT were found
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-15
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
编号:NCT02442752登记状态:入组前撤回企业 / 申办者:Takeda
药物 / 成分:Dexlansoprazole
登记的停止原因(原文):Withdrawn: Business decision (no enrollment)
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-13
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
编号:NCT03719560登记状态:入组前撤回企业 / 申办者:Brown University
药物 / 成分:Methotrexate、Cytarabine
登记的停止原因(原文):lack of funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-13
Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
编号:NCT03768531登记状态:入组前撤回企业 / 申办者:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
药物 / 成分:Nivolumab、Cabrilizumab
登记的停止原因(原文):No subjects were enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-10
Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency
编号:NCT03814798登记状态:入组前撤回企业 / 申办者:Grifols Therapeutics LLC
药物 / 成分:IGSC 20% daily push versus every 2 weeks pump、IGSC 20% daily push versus once a week pump、IGSC 20% daily push versus 2 times per week pump、IGSC 20% 150 mg/kg
登记的停止原因(原文):Due to the regulatory approval of the product in this indication, a large portion of the study becomes unnecessary.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-10
Platelet Transfusion in Sepsis Trial
编号:NCT03968484登记状态:入组前撤回企业 / 申办者:University Hospital Tuebingen
药物 / 成分:platelet transfusion
登记的停止原因(原文):COVID-19 trials gained priority
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-08
Quetiapine Treatment for Pediatric Delirium
编号:NCT03572257登记状态:入组前撤回企业 / 申办者:Medical College of Wisconsin
药物 / 成分:Quetiapine、Placebo
登记的停止原因(原文):Closed due to inability to enroll
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-08
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.
编号:NCT04069234登记状态:入组前撤回企业 / 申办者:Region Skane
药物 / 成分:Ticagrelor、Clopidogrel
登记的停止原因(原文):Sponsor decided to stop the study due to commercial reasons.
查看官方原始记录 ↗